{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.85","upperLimit":"1.0","value":"0.93"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"1.0","value":"1.0"},{"groupId":"OG002","lowerLimit":"0.86","upperLimit":"1.0","value":"0.94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Survival probability of patients alive 18 months from ASCT, time-to-event","dispersionType":"90% Confidence Interval","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"18 Months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"survival probability"}